Micromet’s BiTE® (bi-specific T-cell engagers) antibody platform has now attracted the attention of Amgen. The two companies will collaborate on the discovery and development of BiTE antibodies against three undisclosed solid tumour targets in a deal worth approximately US$1 B. Micromet will be primarily responsible for the discovery and preclinical development of the BiTE antibodies and Amgen will lead the clinical development, manufacturing and commercialisation of any resulting products.